AdvSM
Showing 1 - 7 of 7
Advanced Systemic Mastocytosis Trial (BLU-263, Azacitidine)
Not yet recruiting
- Advanced Systemic Mastocytosis
- (no location specified)
Nov 2, 2022
Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia Trial
Completed
- Aggressive Systemic Mastocytosis
- +3 more
-
Stanford, California
- +10 more
Jan 12, 2023
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematological Tumor
Approved for marketing
- Advanced Systemic Mastocytosis
- +3 more
- (no location specified)
Oct 5, 2021
Avapritinib Versus Best Available Therapy in Patients With AdvSM
Completed
- Advanced Systemic Mastocytosis
- +3 more
-
Palo Alto, California
- +5 more
Dec 17, 2021
Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Tumor (SM-AHN), Mast Cell Leukemia (MCL) Trial in
Recruiting
- Advanced Systemic Mastocytosis (AdvSM)
- +3 more
- CGT9486 tablets
-
Duarte, California
- +10 more
Jul 8, 2022
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Tumor
Active, not recruiting
- Advanced Systemic Mastocytosis
- +3 more
-
Stanford, California
- +31 more
Mar 25, 2022
Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors Trial in Suzhou (Avapritinib)
Recruiting
- Core Binding Factor Acute Myeloid Leukemia
- KIT Mutation-Related Tumors
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital of Soochow University
Apr 7, 2023